TRAIL on trial: preclinical advances in cancer therapy

被引：232

作者：

Stuckey, Daniel W. ^{[1
,2
]}

Shah, Khalid ^{[1
,2
,3
,4
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA

[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA

[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA

[4] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2013年 / 19卷 / 11期

关键词：

TRAIL; apoptesis; cancer; targeted therapy; stem cells; APOPTOSIS-INDUCING LIGAND; MESENCHYMAL STEM-CELLS; MONOCLONAL-ANTIBODY; TUMORICIDAL ACTIVITY; DOWN-REGULATION; GLIOMA-CELLS; IN-VITRO; PHASE-I; DEATH; DELIVERY;

D O I：

10.1016/j.molmed.2013.08.007

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations. In this review, we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models. The successes and failures of the most recent clinical trials using TRAIL agonists are highlighted and we provide a perspective for improving its clinical implementation.

引用

收藏

页码：685 / 694

页数：10

相关论文

共 80 条

[11] Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare [J].

Corsten, Maarten F. ;

Shah, Khalid .

LANCET ONCOLOGY, 2008, 9 (04) :376-384

[12] MicroRNA-21 knockdown disrupts glioma growth In vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas [J].

Corsten, Maarten F. ;

Miranda, Rafael ;

Kasmieh, Randa ;

Krichevsky, Anna M. ;

Weissleder, Ralph ;

Shah, Khalid .

CANCER RESEARCH, 2007, 67 (19) :8994-9000

[13] On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics [J].

Dimberg, L. Y. ;

Anderson, C. K. ;

Camidge, R. ;

Behbakht, K. ;

Thorburn, A. ;

Ford, H. L. .

ONCOGENE, 2013, 32 (11) :1341-1350

[14] Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies [J].

Duiker, E. W. ;

Dijkers, E. C. F. ;

Heerspink, H. Lambers ;

de Jong, S. ;

van der Zee, A. G. J. ;

Jager, P. L. ;

Kosterink, J. G. W. ;

de Vries, E. G. E. ;

Lub-de Hooge, M. N. .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (07) :2203-2212

[15] TRAIL signalling: Decisions between life and death [J].

Falschlehner, Christina ;

Emmerich, Christoph H. ;

Gerlach, Bjoern ;

Walczak, Henning .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (7-8) :1462-1475

[16] Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5) [J].

Forero-Torres, Andres ;

Shah, Jatin ;

Wood, Tina ;

Posey, James ;

Carlisle, Ronda ;

Copigneaux, Catherine ;

Luo, Feng ;

Wojtowicz-Praga, Slawomir ;

Percent, Ivor ;

Saleh, Mansoor .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2010, 25 (01) :13-19

[17] Programmed Cell Death in Animal Development and Disease [J].

Fuchs, Yaron ;

Steller, Hermann .

CELL, 2011, 147 (04) :742-758

[18] Mitochondria: master regulators of danger signalling [J].

Galluzzi, Lorenzo ;

Kepp, Oliver ;

Kroemer, Guido .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (12) :780-788

[19] Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs [J].

Ganten, TM ;

Koschny, R ;

Sykora, J ;

Schulze-Bergkamen, H ;

Büchler, P ;

Haas, TL ;

Schader, MB ;

Untergasser, A ;

Stremmel, W ;

Walczak, H .

CLINICAL CANCER RESEARCH, 2006, 12 (08) :2640-2646

[20] Lessons from the Cancer Genome [J].

Garraway, Levi A. ;

Lander, Eric S. .

CELL, 2013, 153 (01) :17-37

← 1 2 3 4 5 6 7 8 →